High-quality remission: Potential benefits of the melatonergic approach for patients with major depressive disorder

International Clinical Psychopharmacology

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Lam, Raymond W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Agomelatine; Antidepressant; Major depressive disorder; Relapse; Remission; Residual symptoms

Indexed keywords

AGOMELATINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ESZOPICLONE; FLUOXETINE; MIRTAZAPINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AUTONOMIC NEUROPATHY; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; INSOMNIA; MAJOR DEPRESSION; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; REMISSION; REVIEW; RISK ASSESSMENT; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PSYCHOLOGY; SOMNOLENCE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; HYPNOTICS AND SEDATIVES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C;

EID: 34948883276     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yic.0000277959.60604.d1     Document Type: Review

References (43)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 420:21-27.
2. American Psychiatric Association (2000). Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (Suppl 4):1-45.
3. 2 receptors. Naunyn Schmiedebergs Arch Pharmacol 367:553-561.
4. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ (2006). What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67:1428-1434.
5. Bauer M, Whybrow PC, Angst J, Versiani M, Moller H-J (2002). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3:5-43.
6. Ebmeier KP, Donaghey C, Steele JD (2006). Recent developments and current controversies in depression. Lancet 367:153-167.
7. Fava GA, Ruini C, Belaise C (2007). The concept of recovery in major depression. Psychol Med 37:307-317.
8. Fava M (2006). Pharmacological approaches to the treatment of residual symptoms. J Psychopharmacol 20:29-34.
9. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, et al. (2006). Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59:1052-1060.
10. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. (1991). Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851-855.
11. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653-661.
12. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. (1998). A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694-700.
13. Judd LL, Schettler PJ, Akiskal HS (2002). The prevalence, clinical relevance, and public health significance of subthreshold depressions. Psychiatr Clin North Am 25:685-698.
14. Keller MB (2003). Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA 289:3152-3160.
15. Kennedy SH (2007). Agomelatine: an antidepressant with a novel mechanism of action. Future Neurol 2:145-151.
16. Kennedy SH, Emsley R (2006). Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 16:93-100.
17. Kennedy SH, Lam RW, Cohen NL, Ravindran AV (2001). Clinical guidelines for the treatment of depressive disorders. IV. Pharmacotherapy and other biological treatments. Can J Psychiatry 46 (Suppl 1):38S-58S.
18. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289:3095-3105.
19. Kupfer DJ (2005). Achieving adequate outcomes in geriatric depression: standardized criteria for remission. J Clin Psychopharmacol 25:S24-S28.
20. Lam RW (2006). Sleep disturbances and depression: a challenge for antidepressants. Int Clin Psychopharmacol 21 (Suppl 1):S25-S29.
21. Lam RW, Kennedy SH (2004). Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. Can J Psychiatry 49:17S-26S.
22. Loo H, Hale A, D'haenen H (2002). Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 17:239-247.
23. Lustberg L, Reynolds CF (2000). Depression and insomnia: questions of cause and effect. Sleep Med Rev 4:253-262.
24. Mayers AG, Baldwin DS (2005). Antidepressants and their effect on sleep. Hum Psychopharmacol 20:533-559.
25. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. (2003). The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 306:954-964.
26. Mintz J, Mitz LI, Arruda MJ, Hwang SS (1992). Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 49:761-768.
27. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F (2001). Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the study of psychotropic-related sexual dysfunction. J Clin Psychiatry 62 (Suppl 3):10-21.
28. Montgomery SA (2006). Why do we need new and better antidepressants? Int Clin Psychopharmacol 21 (Suppl 1):S1-S10.
29. Nierenberg AA, Keefe BR, Leslie VC, Alpert JE, Pava JA, Worthington JJ III, et al. (1999). Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry 60:221-225.
30. 2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661-673.
31. Papakostas GI, Thase ME, Fava M, Craig Nelson J, Shelton RC (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry (in press).
32. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995). Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171-1180.
33. Quera Salva MA, Vanier B, Laredo J, Hartley S, Chapotot F, Moulin C, et al. (2007). Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol 10:691-696.
34. Riso LP, Thase ME, Howland RH, Friedman ES, Simons AD, Tu XM (1997). A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. J Affect Disord 43:131-142.
35. Rouillon F (2006). Efficacy and tolerance profile of agomelatine and practical use in depressed patients. Int Clin Psychopharmacol 21 (Suppl 1):S31-S35.
36. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. (2006a). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242.
37. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. (2006b). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905-1917.
38. Van Londen L, Molenaar RPG, Goekoop JG, Zwinderman AH, Rooijmans HGM (1998). Three- to 5-year prospective follow-up of outcome in major depression. Psychol Med 28:731-735.
39. Wilson S, Argyropoulos S (2005). Antidepressants and sleep: a qualitative review of the literature. Drugs 65:927-947.
40. Yous S, Andrieux J, Howell HE, Morgan PJ, Renard P, Pfeiffer B, et al. (1992). Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 35:1484-1486.
41. Zimmerman M, Chelminski I, Posternak M (2004). A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. J Nerv Ment Dis 192:595-601.
42. Zimmerman M, Posternak MA, Chelminski I (2005). Is the cutoff to define remission on the Hamilton Rating Scale for Depression too high? J Nerv Ment Dis 193:170-175.
43. Zupancic M, Guilleminault C (2006). Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 20:981-992.